ARIUS announces changes to Board of Directors

TORONTO, May 2 /CNW/ - ARIUS Research Inc., (TSX: ARI), a biotechnology company discovering and developing the next wave of antibody therapeutics, today announced that Mr. Joseph Zakrzewski has been appointed to the Company's Board of Directors.

"Mr. Zakrzewski has a tremendous depth of industry experience and we anticipate he will contribute significantly as ARIUS advances to the next level. We are very pleased to welcome Joe to our Board," said Dr. David Young, Chairman, President and CEO of ARIUS.

Most recently Mr. Zakrzewski was COO at Reliant Pharmaceuticals Inc. a specialty pharmaceutical company focusing on cardiovascular products where he played a significant role in the successful operation and optimization of its pharmaceutical business. He brings more than 19 years of diverse experience in the pharmaceutical industry, primarily at Eli Lilly and Company where he was Vice President of Corporate Business Development, responsible for all business development transactions globally. Prior to this, he held positions of increasing responsibility in a variety of roles in research and development, manufacturing and finance. He has a B.S. in Chemical Engineering, an M.S. in Biochemical Engineering from Drexel University and a MBA in Finance from Indiana University. Mr. Zakrzewski is also a member of the Board of Trustees of the Licensing Executives Society.

Following the announcement at the Company's Annual General Meeting of Mr. Mitchell Kaye's intention to step aside, the Company also announced today that Mr. Kaye has resigned from the Board of Directors. Mr. Mitchell D. Kaye is the Chief Executive Officer, and a founding partner of Xmark Opportunity Partners, LLC. "We wish to thank Mitch for his contributions and dedication to ARIUS," added Dr. Young "He has been generous with his time and insights and I want to thank Mitch for his continued support of the Company."

About ARIUS

ARIUS is a biotechnology company discovering and developing the next wave of antibody therapeutics. Established in 1999, ARIUS has built a proprietary technology platform, FunctionFIRST(TM), that rapidly identifies and selects antibodies based on their functional ability to affect disease. This antibody generation engine has enabled ARIUS to assemble a portfolio of more than 400 antibody candidates. In addition to the antibodies it is developing in-house, ARIUS has ongoing partnerships with key biotechnology and drug development companies. ARIUS is listed on the TSX under the symbol "ARI". For further information, visit www.ariusresearch.com

Forward-Looking Statements

Certain statements in this news release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, which involve known and unknown risks, uncertainties and other factors that may cause our actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. Forward-looking statements in this release include, but are not limited to, ARIUS successfully advancing its new product programs as well as licensing opportunities. These statements are only predictions and actual events or results may differ materially. Factors that could cause such actual events or results expressed or implied by such forward-looking statements to differ materially from any future results expressed or implied by such statements include, but are not limited to: early stage of development; technology and product development; dependence on and management of current and future corporate collaborations; future capital needs; uncertainty of additional funding; no assurance of market acceptance; dependence on proprietary technology and uncertainty of patent protection; intense competition; manufacturing and market uncertainties; and government regulation. These and other factors are described in detail in ARIUS' Annual Report, forthcoming news releases and other filings with Canadian securities regulatory authorities available at www.sedar.com. Forward-looking statements are based on our current expectations and ARIUS is not obligated to update such information to reflect later events or developments.

 The TSX has not reviewed and does not accept responsibility for the
               adequacy or accuracy of this statement.

%SEDAR: 00013708E